187 related articles for article (PubMed ID: 12461013)
1. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
Jones RN; Deshpande LM; Mutnick AH; Biedenbach DJ
J Antimicrob Chemother; 2002 Dec; 50(6):915-32. PubMed ID: 12461013
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
Sader HS; Johnson DM; Jones RN
Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.
Deshpande LM; Jones RN
Clin Microbiol Infect; 2003 Nov; 9(11):1120-4. PubMed ID: 14616730
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Jones RN; Jenkins SG; Hoban DJ; Pfaller MA; Ramphal R
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):93-8. PubMed ID: 10863103
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
Deshpande L; Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):73-5. PubMed ID: 15380281
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
14. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
19. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.
Jones RN; Hare RS; Sabatelli FJ;
J Antimicrob Chemother; 2001 Jan; 47(1):15-25. PubMed ID: 11152427
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.
Erwin ME; Varnam D; Jones RN
Diagn Microbiol Infect Dis; 1997 Jun; 28(2):93-100. PubMed ID: 9239501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
